Tyvaso Inhaled denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for tyvaso inhaled are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Tyvaso Inhaled as Duplicate Therapy

Cigna may issue a duplicate-therapy denial for Tyvaso (inhaled treprostinil) when its records show that another prostacyclin-pathway agent — inhaled, oral, subcutaneous, or intravenous — is already active on your profile, or when a prior authorization for a similar agent in the same drug class was recently approved. The insurer's position is that two agents acting on the same pathway represent redundant therapy without incremental clinical justification.

This denial is frequently challengeable in pulmonary arterial hypertension (PAH) management, where combination therapy across pathways — and sometimes within a pathway — is supported by current guidelines for patients who have not achieved treatment goals on monotherapy or lower-intensity combination regimens. The key is documenting your current functional status, the clinical gap that the existing therapy has not closed, and the specific clinical rationale from your treating pulmonologist for adding or transitioning to inhaled treprostinil.

## Federal Appeal Framework

Under ACA Section 2719, you are entitled to a full internal appeal and, upon final internal denial, independent external review by an accredited IRO. File the internal appeal within 180 days of the denial notice. Request external review within approximately 4 months of the final internal decision. If your clinical condition is deteriorating or a treatment delay poses a health risk, explicitly request expedited review — decisions are typically required within days. ERISA employer plans carry equivalent rights under Section 503.

## Concrete Appeal Steps

1. Request the specific clinical policy Cigna applied and identify exactly which active therapy it used as the basis for the duplicate finding. 2. Confirm whether that therapy is still active, at what dose/route, and what response has been achieved. 3. Have your pulmonologist document the clinical rationale for adding inhaled treprostinil as distinct from, or complementary to, the existing therapy. 4. Compile functional assessments showing the gap between current clinical status and treatment goals. 5. File the internal appeal with a complete clinical package; set a calendar reminder for the external review window.

## Documentation to Gather

• Diagnosis confirmation: Confirmed PAH diagnosis, including WHO/functional class documented in recent chart notes.
• Current therapy records: List of all active PAH therapies, routes of administration, start dates, and documented clinical response.
• Functional status assessments: Six-minute walk test results, functional class assessments, and any hemodynamic data from right heart catheterization, with dates.
• Treatment-goal gap documentation: Clinical notes documenting that treatment goals (as defined by applicable PAH guidelines, e.g., from CHEST, AHA/ACC, or ESC/ERS) have not been achieved on current therapy.
• Pulmonologist medical-necessity letter: Explicitly addresses why inhaled treprostinil is clinically distinct in route, mechanism delivery, or additive benefit — not duplicative — and cites applicable guideline support.

## Criteria-Mapping Structure

Obtain Cigna's coverage policy for inhaled treprostinil and its duplicate-therapy criteria. For each criterion, map the relevant chart fact: the specific active therapy Cigna identified, the clinical response achieved, the functional gap remaining, and the oncologist/pulmonologist's rationale for the combination. A side-by-side comparison demonstrating that the two therapies serve distinct clinical roles — rather than a general appeal letter — is the most persuasive format.